Loading...
Conventional treatments for generalized myasthenia gravis — corticosteroids and immunosuppressants — can have deleterious side effects and a long latency until effectiveness, and some patients remain refractory. Two industry-sponsored, international, double-blind, placebo-controlled trials have now examined the effectiveness and safety of novel monoclonal antibodies, in addition to stable-dose standard treatments, for inadequately controlled generalized myasthenia gravis.
In a phase 3 trial, Antozzi and colleagues randomly assigned 199 adults with a suboptimal response to stable, standard-of-care treatment (Myasthenia Gravis Activities of Daily Living [MG-ADL] score ≥6) to nipocalimab, an investigational (not FDA approved) high affinity neon…